Effect of homocysteinylation on high density lipoprotein physico-chemical properties

Chemistry and Physics of Lipids

Volumn 163, Issue 2, 2010, Pages 228-235

  Ferretti, Gianna ^a   Bacchetti, Tiziana ^a   Masciangelo, Simona ^b   Bicchiega, Virginia ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale S Giuseppe   (Italy)

Author keywords

ApoAI; Atherosclerosis; High density lipoproteins (HDL); Homocysteine (Hcy); Homocysteine thiolactone (HcyT); Lipid peroxidation; Paraoxonase (PON1); Thiolactonase (Htase)

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; TRYPTOPHAN;

ARTICLE; ENZYME ACTIVITY; ENZYME PURIFICATION; IN VITRO STUDY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

2-NAPHTHYLAMINE; ARYLDIALKYLPHOSPHATASE; DITHIOTHREITOL; FLUORESCENT DYES; HOMOCYSTEINE; LAURATES; LIPOPROTEINS, HDL; OXIDATIVE STRESS; PROTEIN CONFORMATION; SPECTROMETRY, FLUORESCENCE; TRYPTOPHAN;

EID: 74149091653     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2009.11.008     Document Type: Article

References (51)

1. Aviram M., Lund-Katz S., Phillips M.C., and Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J. Biol. Chem. 263 (1988) 16842-168428
2. Bowry V.W., Stanley K.K., and Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10316-10320
3. Bradford M.A. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
4. Calvo C., Ponsin G., and Berthezene F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabetes Metab. 14 (1988) 264-269
5. Cohen D.E., and Armstrong E.J. Pharmacology of cholesterol and lipoprotein metabolism. Principles of Pharmacology. 2nd ed. (2007), Lippincott, Williams and Wilkins, Philadelphia, PA 417-438
6. Chung B.H., Segrest J.P., Ray M.J., Brunzell J.D., Hokanson J.E., Krauss R.M., Beaudrie K., and Cone J.T. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 128 (1986) 181-209
7. Chwatko G., and Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal. Biochem. 337 (2005) 271-277
8. Dachet C., Motta C., Neufcour D., and Jacotot B. Fluidity changes and chemical composition of lipoproteins in type IIa hyperlipoproteinemia. Biochim. Biophys. Acta 1046 (1990) 64-72
9. Davidson W.S., and Thompson T.B. The structure of apolipoprotein A-I in high density lipoproteins. J. Biol. Chem. 282 (2007) 22249-22253
10. Dousset N., Ferretti G., Taus M., Valdiguiè P., and Curatola G. Fluorescence analysis of lipoprotein peroxidation. Methods Enzymol. 233 (1994) 459-469
11. Feig J.E., Shamir R., and Fisher E.A. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr. Drug. Targets 9 (2008) 196-203
12. Ferguson E., Hogg N., Antholine W.E., Joseph J., Singh R.J., Parthasarathy S., and Kalyanaraman B. Characterization of the adduct formed from the reaction between homocysteine-thiolactone and low-density lipoprotein: antioxidant implications. Free Radic. Biol. Med. 26 (1999) 968-977
13. Ferretti G., Bacchetti T., Marchionni C., Caldarelli L., and Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 38 (2001) 163-169
14. Ferretti G., Bacchetti T., Marotti E., and Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 52 (2003) 146-151
15. Ferretti G., Marchionni C., Bacchetti T., Galeazzi T., and Dousset N. Effect of aluminium on lipid peroxidation of human high density lipoproteins. Free Radic. Res. 37 (2003) 515-521
16. Ferretti G., Bacchetti T., Moroni C., Vignini A., Nanetti L., and Curatola G. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J. Cell. Biochem. 92 (2004) 351-360
17. Ferretti G., Bacchetti T., Busni D., Rabini R.A., and Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 2957-2962
18. Ferretti G., Bacchetti T., Moroni C., Savino S., Liuzzi A., Balzala F., and Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J. Clin. Endocrinol. Metab. 90 (2005) 1728-1733
19. Ferretti G., Bacchetti T., Nègre-Salvayre A., Salvayre R., Dousset N., and Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 184 (2006) 1-7
20. Francis G.A. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim. Biophys. Acta 1483 (2000) 217-235
21. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44 (2005) 11843-11854
22. Holven K.B., Aukrust P., Retterstøl K., Otterdal K., Bjerkeli V., Ose L., Nenseter M.S., and Halvorsen B. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J. Nutr. 138 (2008) 2070-2075
23. Hu M.L. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 233 (1994) 380-385
24. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 272 (1997) 1935-1942
25. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13 (1999) 2277-2283
26. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
27. Jakubowski H., Zhang L., Bardeguez A., and Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 87 (2000) 45-51
28. Jakubowski H., Ambrosius W.T., and Pratt J.H. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 491 (2001) 35-39
29. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J. Biol. Chem. 277 (2002) 30425-30428
30. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol. Life Sci. 61 (2004) 470-487
31. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin. Chem. Lab. Med. 43 (2005) 1011-1014
32. Jakubowski H. Pathophysiological consequences of homocysteine excess. J. Nutr. 136 (2006) 1741S-1749S
33. Jakubowski H., Perla-Kajan J., Finnell R.H., Cabrera R.M., Wang H., Gupta S., Kruger W.D., Kraus J.P., and Shih D.M. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J. 23 (2009) 1721-1727
34. James R.W., and Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 7 (2004) 1986-1994
35. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin. Chem. Lab. Med. 44 (2006) 1052-1059
36. Kerkeni M., Addad F., Chauffert M., Chuniaud L., Miled A., Trivin F., and Maaroufi K. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin. Biochem. 39 (2006) 821-825
37. Kerkeni M., Letaief A., Achour A., Miled A., Trivin F., and Maaroufi K. Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clin. Biochem. 42 (2009) 777-782
38. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., and Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic. Biol. Med. 41 (2006) 1031-1040
39. Nguyen S.D., and Sok D.E. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic. Res. 37 (2003) 1319-1330
40. Nishio E., and Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236 (1997) 289-293
41. Parasassi T., De Stasio G., Ravagnan G., Rusch R.M., and Gratton E. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys. J. 60 (1991) 179-189
42. Perna A.F., Satta E., Acanfora F., Lombardi C., Ingrosso D., and De Santo N.G. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int. 69 (2006) 869-876
43. Rietzschel E.R., Langlois M., De Buyzere M.L., Segers P., De Bacquer D., Bekaert S., Cooman L., Van Oostveldt P., Verdonck P., De Backer G.G., Gillebert T.C., and Asklepios Investigators. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension 52 (2008) 535-541
44. Rock W., Rosenblat M., Miller-Lotan R., Levy A.P., Elias M., and Aviram M. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 56 (2008) 8704-8713
45. Rozenberg O., and Aviram M. S-glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem. Biophys. Res. Commun. 351 (2006) 492-498
46. Saito H., Dhanasekaran P., Nguyen D., Holvoet P., Lund-Katz S., and Phillips M.C. Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J. Biol. Chem. 278 (2003) 23227-23232
47. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., and La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2214-2225
48. Türkeli, H., Cayci{dotless}, T., Akgül, E.O., Macit, E., Yaman, H., Aydi{dotless}n, I., Demirin, H., Alacam, H., Ozkan, E., Caki{dotless}r, E., Deren, O., Erbil, M.K., Kunak, Z.I., Burat, K., Akman, S., 2009. Paraoxonase-1 activity determination via paraoxon substrate yields no significant difference in mild hyperhomocysteinemia. Int. J. Cardiol. [Epub ahead of print].
49. Undas A., Perla J., Lacinski M., Trzeciak W., Kazmierski R., and Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 35 (2004) 1299-1304
50. Undas A., Jankowski M., Twardowska M., Padjas A., Jakubowski H., and Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb. Haemost. 93 (2005) 346-350
51. Ylä-Herttuala S. Oxidized LDL and atherogenesis. Ann. N. Y. Acad. Sci. 874 (1999) 134-137